StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

Immunocore cash

Cash and short-term investments held at the end of each period.

Immunocore's cash was $880.21M at Jun 30, 2026. For fiscal 2025 it was $864.15M, up 5.3% from the year before. The highest annual figure on record is $864.15M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$864.15M+5.3%
FY2024Dec 31, 2024$820.38M+85.3%
FY2023Dec 31, 2023$442.63M+10.0%
FY2022Dec 31, 2022$402.47M+25.3%
FY2021Dec 31, 2021$321.08M+81.8%
FY2020Dec 31, 2020$176.66M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$880.21M-0.3%
Q1 FY2026Mar 31, 2026$844.90M+0.9%
Q4 FY2025Dec 31, 2025$864.15M+5.3%
Q3 FY2025Sep 30, 2025$892.35M-1.0%
Q2 FY2025Jun 30, 2025$882.81M+2.7%
Q1 FY2025Mar 31, 2025$837.03M+0.5%
Q4 FY2024Dec 31, 2024$820.38M+85.3%
Q3 FY2024Sep 30, 2024$901.28M+102.9%
Q2 FY2024Jun 30, 2024$859.60M+99.0%
Q1 FY2024Mar 31, 2024$832.82M+99.1%
Q4 FY2023Dec 31, 2023$442.63M+10.0%
Q3 FY2023Sep 30, 2023$444.14M+38.3%
Q2 FY2023Jun 30, 2023$432.00M+144.5%
Q1 FY2023Mar 31, 2023$418.38M–
Q4 FY2022Dec 31, 2022$402.47M–
Q4 FY2021Dec 31, 2021$321.08M–
Q4 FY2020Dec 31, 2020$176.66M–

More Immunocore figures

See a number that looks wrong?